RxDoctor Payments Data

Catherine Gaines, PA

Surgical · Lumberton, NCNPI 1063458941

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 205 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Among surgical clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,635in general payments, 2019–2025

Across 205 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$447
  • Bristol Myers Squibb$438
  • Johnson & Johnson$357
  • Pfizer$293
  • Novartis$242
  • GSK$153
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$3,40594%
  • Education$2316%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,635 in reported general payments places this provider in the 95th percentile of 248 surgical providers in North Carolina.

See all surgical providers in North Carolina

Medicare billing

Part B allowed, 2024
$28,874
Medicare patients
194
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate11$213,560
EliquisApixaban41$47,281
Letrozole89$1,723
Tamoxifen Citrate51$1,153
Gabapentin60$816
Potassium Chloride37$553
Anastrozole65$431
Alendronate Sodium39$424
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$419
Olanzapine13$328
Oxycodone Hcl21$311
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav28$223
Mirtazapine20$159
Pregabalin25$141
Losartan Potassium13$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$24$213,56011 claims
PfizerEliquis$293$47,28141 claims
Lilly USA, LLCOlanzapine$140$32813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 surgical providers in North Carolina.

Other surgical in Lumberton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →